NCT00002202已完成3 期
A Phase III Trial to Compare the Safety and Antiviral Efficacy of 141W94 With Indinavir in Combination With Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy, in NRTI-Experienced, Protease Inhibitor (PI)-Naive, HIV-1-Infected Patients.
Glaxo Wellcome46 个研究点 分布在 1 个国家目标入组 460 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 460
- 试验地点
- 46
研究概览
简要总结
The purpose of this study is to see if 141W94 is as safe and effective as indinavir when used with nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. This study also examines what effect other drugs have on how the body handles 141W94.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •Documented HIV infection.
- •HIV RNA >= 400 copies/ml within 14 days prior to randomized study drug administration.
- •No active AIDS-defining opportunistic infection or disease.
- •Signed, informed consent from parent or legal guardian of patients less than 18 years of age.
排除标准
- •Co-existing Condition:
- •Patients with the following conditions or symptoms are excluded:
- •Unlikely to complete the randomized dosing period.
- •Malabsorption syndrome or other gastrointestinal dysfunction that might interfere with drug absorption or ability to take oral medications.
- •Serious medical conditions (e.g., diabetes, cardiac dysfunction, hepatitis) that would compromise patient safety.
- •Concurrent Medication:
- •Cytotoxic chemotherapeutic agents (except local treatment for Kaposi's sarcoma).
- •Investigational treatments (treatment through Treatment IND or expanded-access programs are evaluated individually).
- •Immunomodulating agents such as systemic, high-dose corticosteroids, interleukins, or interferons.
- •Terfenadine, astemizole, cisapride, triazolam, midazolam, and ergotamine/dihydroergotamine-containing regimens.
- •Concurrent Treatment:
- •Radiation therapy (except local treatment for Kaposi's sarcoma).
- •Patients with the following prior conditions are excluded:
- •Clinically relevant pancreatitis or hepatitis within the last 6 months.
- •Prior Medication:
- •Cytotoxic chemotherapeutic agents within 30 days of study drug administration (except local treatment for Kaposi's sarcoma).
- •Protease inhibitor therapy.
- •Dose of vaccine through an investigational HIV vaccine trial within the 3 months prior to study drug administration.
- •Immunomodulating agents such as systemic, high-dose corticosteroids, interleukins, or interferons within 30 days of study drug administration.
- •Prior Treatment:
- •Radiation therapy within 30 days prior to study drug administration (except local treatment for Kaposi's sarcoma).
- •Risk Behavior:
- •Current alcohol or illicit drug use that may interfere with drug absorption or ability to take oral medication.
- •NRTI therapy at day of entry and up to screening.
- •>= 12 weeks of NRTI therapy.
研究者
研究点 (46)
Loading locations...
相似试验
已完成
3 期
A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected PatientsHIV InfectionsNCT00002195Glaxo Wellcome290
已完成
1 期
A Study of 141W94 in Combination With Other Anti-HIV DrugsHIV InfectionsNCT00002372Glaxo Wellcome48
已完成
不适用
A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV DrugsHIV InfectionsNCT00002217Glaxo Wellcome
已完成
3 期
Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)Hepatitis C, ChronicNCT01405560Merck Sharp & Dohme LLC42
已完成
1 期
A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV InfectionHIV InfectionsNCT00002183Glaxo Wellcome60